DEFA14A: Centessa Pharmaceuticals Advances Key Pipeline Programs, Extends Cash Runway into 2027 Amid Strategic Portfolio Shifts

Centessa Pharmaceuticals PLC announced its 2024 annual results, highlighting significant progress in its orexin receptor 2 (OX2R) agonist pipeline, an extended cash runway into 2027, and a new licensing deal, alongside strategic discontinuations of other development programs.

Summary

• Centessa Pharmaceuticals PLC reported a group loss of $235.8 million for the year ended December 31, 2024, an increase from $151.1 million in 2023.
• The company's total liquidity, comprising cash and short-term investments, significantly increased to $482.2 million in 2024 from $256.6 million in 2023.
• Management projects that existing cash and short-term investments will be sufficient to fund operations into 2027 without needing to draw on remaining tranches of the Oxford Finance refinancing agreement.
• ORX750, the most advanced OX2R agonist, is progressing in the Phase 2a CRYSTAL-1 study for narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH), with data anticipated in 2025.
• Phase 1 data for ORX750 demonstrated compelling activity in acutely sleep-deprived healthy volunteers, showing significant increases in wakefulness (mean sleep latencies >30 minutes) and a favorable safety and tolerability profile.
• The company is advancing ORX142 and ORX489, its second and third OX2R agonist candidates, respectively, with ORX142 expected to initiate clinical development and share data in 2025.
• Centessa strategically discontinued the clinical development of LB101, a LockBody candidate, in Q1 2025, as Phase 1 data did not support further development of CD47 as a target effector, though the LockBody platform remains under evaluation.
• Global clinical development of SerpinPC for hemophilia B was discontinued in November 2024 to prioritize the OX2R agonist program, citing the need for additional time and investment for a competitive profile in an evolving market.
• A new Loan and Security Agreement for $110 million was entered into with Oxford Finance LLC on December 30, 2024, and a $75 million Note Purchase Agreement with Oberland Capital Management, LLC was fully repaid.
• A licensing agreement with Genmab A/S was announced on February 14, 2025, granting Genmab access to Centessa's LockBody technology platform for up to three targets, with Centessa eligible for an upfront payment of $15 million, potential option fees, significant milestones (approx. $230 million per product), and tiered mid-single-digit royalties.

Sentiment

Score: 8

Explanation: The document presents a generally positive outlook, driven by strong clinical progress in the core OX2R agonist program, particularly ORX750's promising Phase 1 data and advancement to Phase 2a. The significant increase in liquidity and extended cash runway into 2027 provides substantial financial stability. While there were strategic program discontinuations (LB101, SerpinPC), these were framed as capital prioritization decisions, and the Genmab licensing deal for the LockBody platform provides non-dilutive funding and external validation. The increased losses are expected for a clinical-stage biotech, and the overall financial position is robust.

Positives

• Total liquidity (cash and short-term investments) increased significantly to $482.2 million in 2024 from $256.6 million in 2023, enhancing financial stability.
• The company has extended its cash runway into 2027, providing a longer period for clinical development without immediate capital raise pressure.
• Positive Phase 1 data for ORX750 showed compelling activity in increasing wakefulness and a favorable safety profile, supporting its potential as a best-in-class and first-in-class OX2R agonist.
• ORX750 is progressing to Phase 2a CRYSTAL-1 study, with data expected in 2025, which will inform future registrational studies.
• The OX2R agonist pipeline is expanding with ORX142 and ORX489 advancing, indicating a robust future development strategy.
• The licensing agreement with Genmab for the LockBody platform provides an upfront payment of $15 million, potential option fees, significant milestones, and royalties, validating the platform and generating non-dilutive capital.
• Negative cash outflows from operating activities decreased to $142.1 million in 2024 from $160.3 million in 2023, indicating improved operational cash management.

Negatives

• The group loss for the period increased to $235.8 million in 2024 from $151.1 million in 2023.
• Clinical development of LB101 was discontinued in Q1 2025, as Phase 1 data did not support further development of CD47 as a target effector.
• Global clinical development of SerpinPC was discontinued in November 2024 due to the need for additional time and investment to achieve a competitive profile in an evolving market with a recently FDA-approved competing product.
• Parent company cash and cash equivalents decreased to $3.1 million in 2024 from $6.1 million in 2023.
• Parent company net current assets decreased to $3.6 million in 2024 from $7.0 million in 2023.

Risks

• The company has incurred recurring losses and negative cash flows from operations since inception and expects to continue incurring significant expenses and operating losses for the foreseeable future.
• The trading price of the company's American Depositary Shares (ADSs) is highly volatile and could be subject to wide fluctuations due to factors beyond the company's control, including limited trading volume.
• Broad market and industry factors may negatively affect the market price of the company's ADSs, regardless of its actual operating performance.
• An increase in development activity expenses, potentially due to inflation, could adversely affect the company's financial resources and ability to continue operations.
• There is an inherent risk that the audit may not detect some material misstatements in the financial statements, including those due to fraud or non-compliance with laws and regulations.

Future Outlook

Centessa Pharmaceuticals anticipates 2025 to be a 'data-rich year,' with expected clinical data from the Phase 2a CRYSTAL-1 study of ORX750 across all three indications (NT1, NT2, IH), and the initiation of clinical development and data for ORX142 in acutely sleep-deprived healthy volunteers. The company plans to continue expanding its talent pool in 2025 and expresses confidence in its ability to drive long-term value for stakeholders. The existing cash and short-term investments are projected to fund operations into 2027.

Management Comments

• "Centessa is proud to be at the forefront of developing orexin receptor 2 (OX2R) agonists, a groundbreaking new drug class with the potential to transform the standard of care for patients across multiple therapeutic areas." Saurabh Saha, CEO
• "Based on the strength of these data, we believe ORX750 has the potential to be best-in-class and to enable the full range of doses required to meet the needs of patients living with NT1, NT2 and IH." Saurabh Saha, CEO
• "We look forward to sharing data this year and expect the Phase 2a study to enable dose selection for future registrational studies of ORX750." Saurabh Saha, CEO
• "With this ongoing momentum across our pipeline, we expect 2025 to be an exciting, data-rich year for Centessa, bringing us closer to our goal of delivering potential transformative treatment options to patients in need." Saurabh Saha, CEO
• "There is much work ahead and I am confident that we are well-positioned to continue to drive long-term value for the benefit of all our stakeholders." Saurabh Saha, CEO
• "The Company has also continued to prioritize its pipeline consistent with its commitment to manage its resources with timely data, science-driven decisions, and judicial capital allocation." Chair of the Compensation Committee
• "We continue to believe that a significant portion of remuneration of our Executive Directors should be based on achieving objectives designed to create inherent value in the Company, and ultimately on achieving value creation for our shareholders." Chair of the Compensation Committee

Industry Context

Centessa Pharmaceuticals operates in the highly competitive biopharmaceutical sector, focusing on pioneering a new class of OX2R agonists for sleep-wake disorders and neurological conditions, an area with significant unmet patient needs. The strategic decision to discontinue SerpinPC development for hemophilia B reflects the intense competition and rapid evolution in specific therapeutic areas, as evidenced by the recent FDA approval of a competing product. The licensing deal with Genmab for the LockBody platform indicates a strategy to monetize non-core or early-stage assets through partnerships, a common practice in the biotech industry to de-risk and generate non-dilutive capital. The company's emphasis on 'judicious capital and resource allocation' and 'expeditiously evaluating and terminating programs when the data do not support advancement' aligns with best practices for clinical-stage biotech companies managing high R&D costs and pipeline risks.

Comparison to Industry Standards

• The company's focus on OX2R agonists positions it in a novel drug class, aiming for 'best-in-class' and 'first-in-class potential in NT2 and IH,' which, if successful, could set new industry benchmarks for treating excessive daytime sleepiness.
• The discontinuation of SerpinPC for hemophilia B highlights the competitive landscape in rare disease treatments, where new FDA approvals (e.g., gene therapies or novel factor replacements from companies like BioMarin, Pfizer, or Sanofi) can rapidly shift market dynamics and render less competitive profiles unviable.
• The licensing agreement with Genmab, a leading biotechnology company known for its antibody therapeutics, for the LockBody platform, suggests that Centessa's technology holds significant value and potential for broader application, comparable to other platform-centric biotech companies seeking to leverage their intellectual property through partnerships.
• The company's cash runway into 2027 is a strong indicator of financial health for a clinical-stage biotech, often exceeding the typical 12-18 month runway seen in many peers, providing a longer period for clinical development without immediate capital raise pressure.

Management Changes

Corporate Governance

Related Party Transactions

• The Company has taken advantage of the exemption under FRS 102 not to disclose related party transactions with other companies that are wholly owned within the Group.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through the advancement of the OX2R agonist pipeline and strategic capital allocation. The Genmab licensing deal provides non-dilutive value. Share ownership guidelines for executives aim to align interests.
• Employees: The discontinuation of SerpinPC resulted in some employees being terminated or redeployed. The company plans to add new talent, particularly in neuroscience, and maintains competitive remuneration programs and a comprehensive onboarding program.
• Patients: The development of OX2R agonists aims to provide 'transformative treatment options' for individuals with excessive daytime sleepiness and other neurological/neurodegenerative/neuropsychiatric disorders, addressing significant unmet medical needs.
• Suppliers and Business Partners: Centessa aims to build honest, respectful, and reliable relationships, particularly with contract manufacturers for clinical product supply, emphasizing quality.
• Creditors: The new $110 million loan agreement and repayment of previous debt indicate active debt management and a strengthened liquidity position, which is favorable for creditors.

Next Steps

• Share clinical data from the Phase 2a CRYSTAL-1 study of ORX750 across all three indications (NT1, NT2, IH) in 2025.
• Enable dose selection for future registrational studies of ORX750 based on Phase 2a data.
• Initiate clinical development and share clinical data for ORX142 in acutely sleep-deprived healthy volunteers in 2025, subject to IND clearance.
• Continue IND-enabling activities for ORX489.
• Continue to evaluate the LockBody platform for its potential to deliver potent effectors into the tumor microenvironment (TME) while avoiding systemic toxicity, informing ongoing preclinical work.
• Genmab A/S will conduct all research and development activities under the LockBody license agreement.
• The company plans to continue to add additional talent in 2025, particularly in neuroscience.
• Shareholders will vote on the new Directors Remuneration Policy at the Annual General Meeting on June 20, 2025.
• The company will transition to preparing consolidated financial statements in accordance with UK GAAP starting with the next financial year.

Key Dates

Recommendation

Keywords

Centessa Pharmaceuticals, OX2R agonist, ORX750, Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia, Excessive Daytime Sleepiness, ORX142, ORX489, LockBody technology, Biopharmaceutical, Clinical-stage, Drug development, SEC filing, NASDAQ, Pharmaceuticals, Neuroscience, Sleep-wake disorders, Immuno-oncology, Genmab, Clinical trials